3 hours ago · Global
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
What's happening
SignalsMonitor is following this as a technology story. Ars Technica is the outlet attached so far. The reports are tied to Global. The first report grouped here was at 22 Oct 2026, 22:12 UTC. The headline in use is “Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer—reduced the risk of death or recurrence by 42 percent compared to standard treatment in a late-stage trial, pharmaceutical partners Merck and Moderna announced Thursday. The results are a significant advance in melanoma treatment; Merck and Moderna are already engaging with…
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by Ars Technica
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Reported by 1 outlet
- Ars Technica